Johanna C Sierra1, Mohammad Asim1, Thomas G Verriere1, M Blanca Piazuelo1, Giovanni Suarez1, Judith Romero-Gallo1, Alberto G Delgado1, Lydia E Wroblewski1, Daniel P Barry1, Richard M Peek1,2,3, Alain P Gobert1,4, Keith T Wilson1,2,3,4,5. 1. Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 2. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 3. Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 4. Center for Mucosal Inflammation and Cancer, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 5. Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
Abstract
OBJECTIVE: Gastric cancer is the third leading cause of cancer death worldwide and infection by Helicobacter pylori is the strongest risk factor. We have reported increased epidermal growth factor receptor (EGFR) phosphorylation in the H. pylori-induced human carcinogenesis cascade, and association with DNA damage. Our goal was to determine the role of EGFR activation in gastric carcinogenesis. DESIGN: We evaluated gefitinib, a specific EGFR inhibitor, in chemoprevention of H. pylori-induced gastric inflammation and cancer development. Mice with genetically targeted epithelial cell-specific deletion of Egfr (EfgrΔepi mice) were also used. RESULTS: In C57BL/6 mice, gefitinib decreased Cxcl1 and Cxcl2 expression by gastric epithelial cells, myeloperoxidase-positive inflammatory cells in the mucosa and epithelial DNA damage induced by H. pylori infection. Similar reductions in chemokines, inflammatory cells and DNA damage occurred in infected EgfrΔepi versus Egfrfl/fl control mice. In H. pylori-infected transgenic insulin-gastrin (INS-GAS) mice and gerbils, gefitinib treatment markedly reduced dysplasia and carcinoma. Gefitinib blocked H. pylori-induced activation of mitogen-activated protein kinase 1/3 (MAPK1/3) and activator protein 1 in gastric epithelial cells, resulting in inhibition of chemokine synthesis. MAPK1/3 phosphorylation and JUN activation was reduced in gastric tissues from infected wild-type and INS-GAS mice treated with gefitinib and in primary epithelial cells from EfgrΔepi versus Egfrfl/fl mice. Epithelial EGFR activation persisted in humans and mice after H. pylori eradication, and gefitinib reduced gastric carcinoma in INS-GAS mice treated with antibiotics. CONCLUSIONS: These findings suggest that epithelial EGFR inhibition represents a potential strategy to prevent development of gastric carcinoma in H. pylori-infected individuals. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE:Gastric cancer is the third leading cause of cancer death worldwide and infection by Helicobacter pylori is the strongest risk factor. We have reported increased epidermal growth factor receptor (EGFR) phosphorylation in the H. pylori-induced humancarcinogenesis cascade, and association with DNA damage. Our goal was to determine the role of EGFR activation in gastric carcinogenesis. DESIGN: We evaluated gefitinib, a specific EGFR inhibitor, in chemoprevention of H. pylori-induced gastric inflammation and cancer development. Mice with genetically targeted epithelial cell-specific deletion of Egfr (EfgrΔepi mice) were also used. RESULTS: In C57BL/6 mice, gefitinib decreased Cxcl1 and Cxcl2 expression by gastric epithelial cells, myeloperoxidase-positive inflammatory cells in the mucosa and epithelial DNA damage induced by H. pyloriinfection. Similar reductions in chemokines, inflammatory cells and DNA damage occurred in infected EgfrΔepi versus Egfrfl/fl control mice. In H. pylori-infected transgenic insulin-gastrin (INS-GAS) mice and gerbils, gefitinib treatment markedly reduced dysplasia and carcinoma. Gefitinib blocked H. pylori-induced activation of mitogen-activated protein kinase 1/3 (MAPK1/3) and activator protein 1 in gastric epithelial cells, resulting in inhibition of chemokine synthesis. MAPK1/3 phosphorylation and JUN activation was reduced in gastric tissues from infected wild-type and INS-GAS mice treated with gefitinib and in primary epithelial cells from EfgrΔepi versus Egfrfl/fl mice. Epithelial EGFR activation persisted in humans and mice after H. pylori eradication, and gefitinib reduced gastric carcinoma in INS-GASmice treated with antibiotics. CONCLUSIONS: These findings suggest that epithelial EGFR inhibition represents a potential strategy to prevent development of gastric carcinoma in H. pylori-infected individuals. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: M E Hammond; G R Lapointe; P H Feucht; S Hilt; C A Gallegos; C A Gordon; M A Giedlin; G Mullenbach; P Tekamp-Olson Journal: J Immunol Date: 1995-08-01 Impact factor: 5.422
Authors: Giovanni Suarez; Judith Romero-Gallo; M Blanca Piazuelo; Ge Wang; Robert J Maier; Lennart S Forsberg; Parastoo Azadi; Martin A Gomez; Pelayo Correa; Richard M Peek Journal: Cancer Res Date: 2015-03-02 Impact factor: 12.701
Authors: Sabine Brandt; Terry Kwok; Roland Hartig; Wolfgang König; Steffen Backert Journal: Proc Natl Acad Sci U S A Date: 2005-06-21 Impact factor: 11.205
Authors: Wataru Shibata; Shigeo Takaishi; Sureshkumar Muthupalani; D Mark Pritchard; Mark T Whary; Arlin B Rogers; James G Fox; Kelly S Betz; Klaus H Kaestner; Michael Karin; Timothy C Wang Journal: Gastroenterology Date: 2009-12-04 Impact factor: 22.682
Authors: Rupesh Chaturvedi; Mohammad Asim; M Blanca Piazuelo; Fang Yan; Daniel P Barry; Johanna Carolina Sierra; Alberto G Delgado; Salisha Hill; Robert A Casero; Luis E Bravo; Ricardo L Dominguez; Pelayo Correa; D Brent Polk; M Kay Washington; Kristie L Rose; Kevin L Schey; Douglas R Morgan; Richard M Peek; Keith T Wilson Journal: Gastroenterology Date: 2014-02-13 Impact factor: 22.682
Authors: Michael F Smith; Anastasia Mitchell; Guolian Li; Song Ding; Ann Marie Fitzmaurice; Kieran Ryan; Sheila Crowe; Joanna B Goldberg Journal: J Biol Chem Date: 2003-06-13 Impact factor: 5.157
Authors: Giovanni Suarez; Judith Romero-Gallo; Maria B Piazuelo; Johanna C Sierra; Alberto G Delgado; M Kay Washington; Shailja C Shah; Keith T Wilson; Richard M Peek Journal: Cancer Res Date: 2019-01-29 Impact factor: 12.701
Authors: Yvonne L Latour; Johanna C Sierra; Kara M McNamara; Thaddeus M Smith; Paula B Luis; Claus Schneider; Alberto G Delgado; Daniel P Barry; Margaret M Allaman; M Wade Calcutt; Kevin L Schey; M Blanca Piazuelo; Alain P Gobert; Keith T Wilson Journal: J Immunol Date: 2022-07-27 Impact factor: 5.426
Authors: Yvonne L Latour; Johanna C Sierra; Jordan L Finley; Mohammad Asim; Daniel P Barry; Margaret M Allaman; Thaddeus M Smith; Kara M McNamara; Paula B Luis; Claus Schneider; Justin Jacobse; Jeremy A Goettel; M Wade Calcutt; Kristie L Rose; Kevin L Schey; Ginger L Milne; Alberto G Delgado; M Blanca Piazuelo; Bindu D Paul; Solomon H Snyder; Alain P Gobert; Keith T Wilson Journal: JCI Insight Date: 2022-06-22
Authors: Jan Korbecki; Iwona Szatkowska; Patrycja Kupnicka; Wojciech Żwierełło; Katarzyna Barczak; Iwona Poziomkowska-Gęsicka; Jerzy Wójcik; Dariusz Chlubek; Irena Baranowska-Bosiacka Journal: Int J Mol Sci Date: 2022-06-28 Impact factor: 6.208